The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access
The United Kingdom has universal healthcare systems, the National Health System (NHS), in its four nations, with healthcare services provided free of charge at the point of delivery. Approximately 10.5% of the UK population has voluntary supplementary private health insurance. While the provision o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde
2022-06-01
|
| Series: | Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde |
| Online Access: | https://rbfhss.org.br/sbrafh/article/view/804 |
| _version_ | 1828813295090401280 |
|---|---|
| author | Adriana M. IVAMA-BRUMMELL Pilar PINILLA-DOMINGUEZ Aline N. BIZ |
| author_facet | Adriana M. IVAMA-BRUMMELL Pilar PINILLA-DOMINGUEZ Aline N. BIZ |
| author_sort | Adriana M. IVAMA-BRUMMELL |
| collection | DOAJ |
| description |
The United Kingdom has universal healthcare systems, the National Health System (NHS), in its four nations, with healthcare services provided free of charge at the point of delivery. Approximately 10.5% of the UK population has voluntary supplementary private health insurance. While the provision of inpatient medicines is free of charge, medicines provided in the outpatient setting have a dispensing fee in some of the nations, such as the case of England (co-payment). The UK marketing authorisation process is called product licensing and is overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). There are different licensing routes based on the intended market for launch. MHRA also offers early access schemes and pathways for products targeting unmet medical needs and promising technologies, that aim to accelerate and facilitate market and patient access to products in the UK. These schemes include the option for companies to engage early with regulators and other system partners such as health technology assessment (HTA) agencies. As soon as the technology is authorised, it is available at a list price. Prices for medicines are regulated in legislation and in schemes agreed between the industry association and the Department of Health and Social Care (DHSC). The prices for the NHS are negotiated between the government and the companies. Routine funding decisions in the NHS are guided by HTA evaluations informed by agencies such as the National Institute for Health and Care Excellence (NICE) in England, the Scottish Medicines Consortium (SMC) in Scotland, and the All Wales Medicines Strategy Group (AWMSG) in Wales. Many medicines and other technologies are subject to price negotiations in the NHS, sometimes with confidential price agreements. The NHS in England is legally mandated to routinely fund technologies recommended by NICE that have been evaluated by some of its programmes. The other UK nations have similar arrangements or recognise decisions made in England. The role and contribution of NICE and other HTA agencies in ensuring value for money and evidence-based decision making is well recognised worldwide.
|
| first_indexed | 2024-12-12T09:58:18Z |
| format | Article |
| id | doaj.art-6b973df009a842b082bcc4ebd1a76b76 |
| institution | Directory Open Access Journal |
| issn | 2179-5924 2316-7750 |
| language | English |
| last_indexed | 2024-12-12T09:58:18Z |
| publishDate | 2022-06-01 |
| publisher | Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde |
| record_format | Article |
| series | Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde |
| spelling | doaj.art-6b973df009a842b082bcc4ebd1a76b762022-12-22T00:28:04ZengSociedade Brasileira de Farmácia Hospitalar e Serviços de SaúdeRevista Brasileira de Farmácia Hospitalar e Serviços de Saúde2179-59242316-77502022-06-0113210.30968/rbfhss.2022.132.0804The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and accessAdriana M. IVAMA-BRUMMELLPilar PINILLA-DOMINGUEZAline N. BIZ The United Kingdom has universal healthcare systems, the National Health System (NHS), in its four nations, with healthcare services provided free of charge at the point of delivery. Approximately 10.5% of the UK population has voluntary supplementary private health insurance. While the provision of inpatient medicines is free of charge, medicines provided in the outpatient setting have a dispensing fee in some of the nations, such as the case of England (co-payment). The UK marketing authorisation process is called product licensing and is overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). There are different licensing routes based on the intended market for launch. MHRA also offers early access schemes and pathways for products targeting unmet medical needs and promising technologies, that aim to accelerate and facilitate market and patient access to products in the UK. These schemes include the option for companies to engage early with regulators and other system partners such as health technology assessment (HTA) agencies. As soon as the technology is authorised, it is available at a list price. Prices for medicines are regulated in legislation and in schemes agreed between the industry association and the Department of Health and Social Care (DHSC). The prices for the NHS are negotiated between the government and the companies. Routine funding decisions in the NHS are guided by HTA evaluations informed by agencies such as the National Institute for Health and Care Excellence (NICE) in England, the Scottish Medicines Consortium (SMC) in Scotland, and the All Wales Medicines Strategy Group (AWMSG) in Wales. Many medicines and other technologies are subject to price negotiations in the NHS, sometimes with confidential price agreements. The NHS in England is legally mandated to routinely fund technologies recommended by NICE that have been evaluated by some of its programmes. The other UK nations have similar arrangements or recognise decisions made in England. The role and contribution of NICE and other HTA agencies in ensuring value for money and evidence-based decision making is well recognised worldwide. https://rbfhss.org.br/sbrafh/article/view/804 |
| spellingShingle | Adriana M. IVAMA-BRUMMELL Pilar PINILLA-DOMINGUEZ Aline N. BIZ The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde |
| title | The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access |
| title_full | The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access |
| title_fullStr | The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access |
| title_full_unstemmed | The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access |
| title_short | The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access |
| title_sort | regulatory evaluation pricing and reimbursement pathway for medicines in the uk combining innovation and access |
| url | https://rbfhss.org.br/sbrafh/article/view/804 |
| work_keys_str_mv | AT adrianamivamabrummell theregulatoryevaluationpricingandreimbursementpathwayformedicinesintheukcombininginnovationandaccess AT pilarpinilladominguez theregulatoryevaluationpricingandreimbursementpathwayformedicinesintheukcombininginnovationandaccess AT alinenbiz theregulatoryevaluationpricingandreimbursementpathwayformedicinesintheukcombininginnovationandaccess AT adrianamivamabrummell regulatoryevaluationpricingandreimbursementpathwayformedicinesintheukcombininginnovationandaccess AT pilarpinilladominguez regulatoryevaluationpricingandreimbursementpathwayformedicinesintheukcombininginnovationandaccess AT alinenbiz regulatoryevaluationpricingandreimbursementpathwayformedicinesintheukcombininginnovationandaccess |